Skip to main content
Concord Biotech Limited logo

Concord Biotech Limited — Investor Relations & Filings

Ticker · CONCORDBIO ISIN · INE338H01029 LEI · 335800FBIZZTLAXLXZ73 BSE.NS Manufacturing
Open in API
Filings indexed 225 across all filing types
Latest filing 2025-01-24 Regulatory Filings
Country IN India
Listing BSE.NS CONCORDBIO

About Concord Biotech Limited

https://concordbiotech.com/

Concord Biotech Limited is a research and development-driven company specializing in the production of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization focuses on niche therapeutic areas, including immunosuppressants, oncology, anti-fungals, and anti-infectives. It maintains a significant global presence, supplying products to regulated markets such as the United States, Europe, and Japan. Concord Biotech operates large-scale fermentation facilities and is recognized for its expertise in complex manufacturing processes. Its operations are vertically integrated, covering the entire value chain from strain development and fermentation to downstream processing and formulation. The company adheres to international quality standards, holding certifications from major regulatory bodies like the USFDA and EUGMP, ensuring the delivery of high-quality pharmaceutical solutions to its global clientele.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a letter from Concord Biotech Limited addressed to stock exchanges notifying about an upcoming Board Meeting scheduled for February 13, 2025. The purpose of the meeting is to consider and approve the unaudited financial results for the third quarter and nine months ended December 31, 2024, along with a limited review report by statutory auditors. The letter also mentions the closure of the trading window in compliance with insider trading regulations. The document is short (2512 characters) and serves as an announcement of a future event and report approval, not the report itself. Therefore, it is an announcement related to financial results and board meeting scheduling, fitting the category of Regulatory Filings (RNS) as it does not contain actual financial data or the full report.
2025-01-24 English
Agreements
Capital/Financing Update Classification · 95% confidence The document is an official communication from Concord Biotech Limited to stock exchanges (NSE and BSE) regarding the company's acquisition of a 26% equity stake in Clean Max Everglades Private Limited. It references compliance with SEBI LODR Regulations, specifically Regulation 30, which pertains to disclosure of material events or information. The content details the terms of the acquisition, including the share purchase agreement, consideration, percentage acquired, and strategic rationale related to renewable energy investment. There is no financial statement or detailed financial performance data presented, nor is this a report or earnings release. Instead, it is an announcement of a capital investment transaction. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is sufficient and the content is substantive about the transaction, not merely a brief notice or report publication announcement.
2025-01-16 English
Agreements
Capital/Financing Update Classification · 95% confidence The document is an official communication from Concord Biotech Limited to stock exchanges (NSE and BSE) regarding the company's acquisition of 26% equity shares in Clean Max Everglades Private Limited. It references compliance with SEBI LODR Regulations, specifically Regulation 30, which pertains to disclosure of material events. The content details the share purchase agreement, the nature of the investment, and annexure with specifics about the target entity and transaction. There are no financial statements or detailed financial performance data presented; rather, it is an announcement of a capital investment transaction. This fits the category of Capital/Financing Update (CAP), as it updates on company fundraising or capital structure changes through acquisition of shares in another company.
2025-01-16 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming dematerialisation activities for the quarter ended December 31, 2024. It is addressed to stock exchanges and signed by the company secretary. The content is a compliance certificate related to securities dematerialisation, not a financial report or announcement of financial results. The document length is short (3666 characters) and primarily serves as a regulatory compliance certificate. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory compliance document and not a financial report or announcement.
2025-01-11 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) informing about the closure of the trading window pursuant to SEBI regulations ahead of the announcement of unaudited financial results for the quarter and nine months ended 31st December 2024. It does not contain any financial data or results itself, nor does it present a report. The document is short (3451 characters) and serves as a regulatory announcement related to insider trading restrictions before financial results are declared. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for such compliance and regulatory announcements that do not fit other specific report types.
2024-12-24 English
Others
Capital/Financing Update Classification · 95% confidence The document is an official communication from Concord Biotech Limited to stock exchanges (NSE and BSE) regarding an investment of USD 1,000,000 in Compulsorily Convertible Notes of Palvella Therapeutics, Inc. It references compliance with Regulation 30 of SEBI LODR Regulations, which pertains to disclosure of material events. The document includes detailed annexure information about the investment, the target entity, and terms of acquisition. There is no financial statement or report data, but rather an update on a capital investment transaction. This fits the category of Capital/Financing Update (CAP), as it informs about a financing activity and capital structure change (investment in convertible notes). The document length and content confirm it is not a brief announcement or a report publication notice, but a substantive update on financing.
2024-12-12 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.